Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
In brief
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men as assessed by the International Prostate Symptom Score (IPSS) at Week 14.
Key facts
- Study ID
- NCT00743184
- Run by
- Spectrum Pharmaceuticals, Inc
- People needed
- 28
- Starts
- 2008-12-04
- Expected to finish
- 2010-01-20
- Last updated by the study team
- 2021-11-22
Who can join
Age: 50 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- California Professional Research — Newport Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.